$ACB earnings report

Aurora Cannabis reported $86.0 million of net revenue, record international medical cannabis net revenue of $61.4 million, $14.0 million of adjusted EBITDA and free cash flow outflow of $17.5 million for fiscal 2027 second quarter. AlphAI read Aurora Cannabis's Fiscal 2027 second quarter filing as mixed. 2 quarters are on record below.

Fiscal 2027 second quarter

AlphAI · Earnings readACB · Fiscal 2027 second quarter · ended September 30, 2026

Aurora Cannabis reported $86.0 million of net revenue, record international medical cannabis net revenue of $61.4 million, $14.0 million of adjusted EBITDA and free cash flow outflow of $17.5 million for fiscal 2027 second quarter.

→Mixed quarter

Net revenue increased 9%, led by a 44% increase in international medical cannabis net revenue, while adjusted gross margin before fair value adjustments declined to 61% from 65%, adjusted EBITDA declined to $14.0 million, and adjusted net income declined to $3.1 million.

Revenue
CA$86M
9% increase y/y
Q2 2027 Canadian medical cannabis
CA$21.2M
24% decrease y/y
Gross margin · GAAP
44 %

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q2 2027 total net revenuenon-GAAPCA$86M–9% increase
Q2 2027 medical cannabis net revenuenon-GAAPCA$82.5M–17% increase
Q2 2027 gross profitGAAPCA$37.55M––
Q2 2027 gross profit before fair value adjustmentsotherCA$43.90M––
Q2 2027 gross marginGAAP44 %––
Q2 2027 gross margin before fair value adjustmentsother51 %––
Q2 2027 adjusted gross margin before fair value adjustments on total net revenuenon-GAAP61%––
Q2 2027 adjusted gross margin before fair value adjustments on medical cannabis net revenuenon-GAAP62%––
Q2 2027 operating expensesGAAPCA$55.48M––
Q2 2027 general and administration expenseGAAPCA$30.27M––
Q2 2027 sales and marketing expenseGAAPCA$17.84M––
Q2 2027 adjusted SG&Anon-GAAPCA$37.4M––
Q2 2027 other income (expenses)GAAP−CA$1.56M––
Q2 2027 net loss from continuing operationsGAAPCA$21.1M–decrease in net loss of $6.1 million
Q2 2027 net loss from discontinued operations, net of taxGAAP—––
Q2 2027 net lossGAAP−CA$21.05M––
Q2 2027 adjusted EBITDAnon-GAAPCA$14M–decrease of $1.4 million
Q2 2027 adjusted net incomenon-GAAPCA$3.1M–decrease of $8.9 million
Q2 2027 net cash used in operating activities from continuing operationsGAAP−CA$14.95M––
Q2 2027 maintenance capital expendituresother−CA$2.59M––
Q2 2027 free cash flownon-GAAPoutflow of $17.5 million–decrease in free cash outflow of $22.4 million
Six months ended September 30, 2026 total net revenuenon-GAAPCA$153.6M––
Six months ended September 30, 2026 medical cannabis net revenuenon-GAAPCA$146.6M––
Six months ended September 30, 2026 gross profitGAAPCA$73.17M––
Six months ended September 30, 2026 gross profit before fair value adjustmentsotherCA$73.10M––
Six months ended September 30, 2026 gross marginGAAP48 %––
Six months ended September 30, 2026 gross margin before fair value adjustmentsother48 %––
Six months ended September 30, 2026 adjusted gross margin before fair value adjustments on total net revenuenon-GAAP60 %––
Six months ended September 30, 2026 adjusted gross margin before fair value adjustments on medical cannabis net revenuenon-GAAP62 %––
Six months ended September 30, 2026 operating expensesGAAPCA$99.83M––
Six months ended September 30, 2026 general and administration expenseGAAPCA$54.87M––
Six months ended September 30, 2026 sales and marketing expenseGAAPCA$33.43M––
Six months ended September 30, 2026 adjusted SG&Anon-GAAPCA$72.47M––
Six months ended September 30, 2026 other income (expenses)GAAPCA$3.54M––
Six months ended September 30, 2026 net loss from continuing operationsGAAP−CA$25.08M––
Six months ended September 30, 2026 net loss from discontinued operations, net of taxGAAP—––
Six months ended September 30, 2026 net lossGAAP−CA$25.08M––
Six months ended September 30, 2026 adjusted EBITDAnon-GAAPCA$17.44M––
Six months ended September 30, 2026 adjusted net incomenon-GAAPCA$6.92M––
Six months ended September 30, 2026 net cash used in operating activities from continuing operationsGAAP−CA$19.39M––
Six months ended September 30, 2026 maintenance capital expendituresother−CA$3.93M––
Six months ended September 30, 2026 free cash flownon-GAAP−CA$23.33M––
Working capital as at September 30, 2026non-GAAPCA$306.8M––
Total current assets as at September 30, 2026GAAPCA$383.4M––
Total current liabilities as at September 30, 2026GAAP−CA$76.64M––

Segments

SegmentRevenueq/qy/y
Q2 2027 Canadian medical cannabisThe decrease was mainly due to changes in the federal reimbursement program effective April 1, 2026.CA$21.2M–24% decrease
Q2 2027 international medical cannabisHigher sales in Germany and Poland driven by increased patient demand.CA$61.4M–44% increase
Q2 2027 consumer cannabisThe decline reflected the strategic shift to focus on Canadian and international medical cannabis and the wind down of the consumer cannabis business.CA$1.6M––
Q2 2027 wholesale bulk cannabisHigher net revenue in wholesale bulk cannabis contributed to the increase in total net revenue.CA$1.87M––

What drove it

  • Total net revenue growth was driven by higher international medical cannabis and wholesale bulk cannabis net revenue, partly offset by lower Canadian medical cannabis revenue and the consumer-cannabis wind down.
  • International medical cannabis sales increased in Germany and Poland due to increased patient demand.
  • Prior-year impairment charges totalled $13.7 million, contributing to the reduction in net loss from continuing operations.
  • Free cash flow outflow improved primarily because working capital investment was $12.6 million compared to $37.2 million in the prior-year period.

Concerns

  • Canadian medical cannabis net revenue declined 24% following changes in the federal reimbursement program effective April 1, 2026.
  • Adjusted gross margin before fair value adjustments on total net revenue declined to 61% from 65%, and medical cannabis adjusted gross margin declined to 62% from 69%, reflecting pricing compression and competitive market dynamics.
  • Consumer cannabis net revenue declined as the Company winds down the channel; consumer cannabis adjusted gross margin before fair value adjustments was 23%, compared to 27%.
  • Adjusted SG&A increased to $37.4 million from $34.9 million, while adjusted EBITDA declined to $14.0 million from $15.4 million.
  • Adjusted net income declined to $3.1 million from $12.0 million, including unfavourable foreign exchange fluctuations of $4.7 million and a $0.8 million decrease in interest and other income.

What to watch

  • The pending transaction under which Organigram will acquire Aurora is expected to be completed in January 2027, subject to shareholder, court and regulatory approvals and other customary closing conditions.
  • The Special Meeting to approve the transaction is expected to be held in December 2026.
  • Continued international medical cannabis demand in Germany and Poland.
  • The effect of federal reimbursement program changes and competitive market dynamics on Canadian medical cannabis revenue and medical-cannabis margins.
  • Execution of the consumer cannabis wind down and related business transformation costs.

Balance sheet and cash flow

  • $133.0 million of cash, cash equivalents and short-term investments, with no debt.
  • Q2 2027 net cash used in operating activities from continuing operations was (14,946 ) ($ thousands), compared to (38,008 ) ($ thousands) in the prior-year period.
  • Q2 2027 free cash flow was an outflow of $17.5 million, compared to an outflow of $39.9 million in the prior-year period.
  • Q2 2027 working capital investment was $12.6 million, compared to $37.2 million in the prior-year period.
  • Working capital was 306,759 ($ thousands) as at September 30, 2026, compared to 299,729 ($ thousands) as at September 30, 2025.

Analysis

Aurora delivered $86.0 million of Q2 2027 total net revenue, up 9% from $78.8 million. Growth was concentrated in medical cannabis, where revenue increased 17% to $82.5 million. International medical cannabis was the principal contributor, increasing 44% to a record $61.4 million on higher sales in Germany and Poland driven by increased patient demand. This more than offset a 24% decline in Canadian medical cannabis revenue to $21.2 million and the ongoing consumer cannabis wind down.

The sales mix continued to move toward international medical cannabis, but profitability metrics weakened. Adjusted gross margin before fair value adjustments on total net revenue was 61%, compared with 65%, while the equivalent medical cannabis margin was 62%, compared with 69%. Aurora attributed the medical margin decline to pricing compression from changes to the federal reimbursement program effective April 1, 2026 and competitive market dynamics. Consumer cannabis margin was 23%, compared with 27%, as the Company sold product at reduced prices during the channel wind down.

Operating costs increased. Adjusted SG&A rose to $37.4 million from $34.9 million, and adjusted EBITDA declined to $14.0 million from $15.4 million despite the $1.1 million increase in adjusted gross profit before fair value adjustments. Adjusted net income declined to $3.1 million from $12.0 million, with the Company citing the increase in adjusted SG&A, unfavourable foreign exchange fluctuations of $4.7 million, and a $0.8 million decline in interest and other income. GAAP net loss from continuing operations improved to $21.1 million from $27.2 million, principally because the prior-year period included $13.7 million of impairment charges.

Cash conversion improved materially. Free cash flow was an outflow of $17.5 million, compared with an outflow of $39.9 million, primarily reflecting a $12.6 million working capital investment compared with $37.2 million in the prior-year period. The Company reported $133.0 million of cash, cash equivalents and short-term investments with no debt. No financial outlook was issued in the release.

The reported quarter is also framed by the definitive agreement for Organigram to acquire Aurora. The transaction is expected to be completed in January 2027, subject to shareholder, court and regulatory approvals and other customary closing conditions. Aurora cancelled the investor call that had been scheduled for November 12, 2026.

Not in the filing

stated, not guessed
  • Earnings per share, including IFRS and adjusted earnings per share.
  • Forward financial guidance for revenue, margins, operating expenses, tax rate, adjusted EBITDA, net income or free cash flow.
  • Prior-quarter comparisons for reported operating metrics.
  • Dividend, share-repurchase or other capital-return information.
  • A detailed debt balance other than the statement that the Company has no debt.
  • Named executive quotations.
  • A current-period income tax expense metric outside the adjusted EBITDA reconciliation. The reconciliation reports income tax expense of 1,553 ($ thousands) for Q2 2027 and 1,956 ($ thousands) for the six months ended September 30, 2026, but no income tax rate was reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Fiscal 2027 first quarter

AlphAI · Earnings readACB · Fiscal 2027 first quarter · ended June 30, 2026

Aurora Cannabis Announces Fiscal 2027 First Quarter Results

→Mixed quarter

International medical cannabis revenue increased 17% and the loss from continuing operations narrowed, but total net revenue declined 9%, adjusted gross margin before fair value adjustments declined to 58%, adjusted EBITDA fell to 3,443 ($ thousands), and free cash flow was an outflow of 5,793 ($ thousands).

Revenue
CA$67.6M
9% decrease y/y
Canadian medical cannabis
CA$20.7M
25% decrease y/y
Gross margin · other
53%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total net revenuenon-GAAPCA$67.55M–9% decrease
Gross profitotherCA$35.62M–increase of $2.1 million
Gross profit before fair value adjustmentsotherCA$29.19M––
Gross marginother53%––
Gross margin before fair value adjustmentsother43%––
Adjusted gross margin before fair value adjustments on total net revenuenon-GAAP58%––
Adjusted gross profit before fair value adjustmentsnon-GAAPCA$39.5M–decrease of $8.3 million
Operating expensesotherCA$44.35M–decrease of $1.1 million
General and administrationotherCA$24.60M––
Sales and marketingotherCA$15.59M––
Adjusted selling, general & administration expensenon-GAAPCA$35.08M–decrease of $1.0 million
Other income (expenses)otherCA$5.10M–increase in other income of $3.4 million
Net loss from continuing operationsother−CA$4.03M–decrease in net loss from continuing operations of $6.2 million
Net income (loss) from discontinued operations, net of taxesother-––
Net lossother−CA$4.03M––
Adjusted net incomenon-GAAPCA$3.81M–decrease of $2.8 million
Adjusted EBITDAnon-GAAPCA$3.44M–decrease of $7.4 million
Net cash provided by (used in) operating activities from continuing operationsother−CA$4.45M––
Maintenance capital expendituresother−CA$1.35M––
Free cash flownon-GAAP−CA$5.79M–decrease in free cash flow of $12.6 million
Income tax expense (recovery)otherCA$403K––
Working capitalnon-GAAPCA$320.0M––
Total current assetsotherCA$393.4M––
Total current liabilitiesother−CA$73.43M––

Segments

SegmentRevenueq/qy/y
Canadian medical cannabisChanges in the federal reimbursement program effective April 1, 2026, which lowered reimbursement rates by approximately 30%.CA$20.70M–25% decrease
International medical cannabisHigher sales in Germany driven by increased patient demand.CA$43.34M–17% increase
Consumer cannabisStrategic shift to focus on Canadian and international medical cannabis and wind down the consumer cannabis business.CA$2.06M––
Wholesale bulk cannabisOffset part of the decrease in total net revenue.CA$1.46M––

Fiscal Full Year 2027 Outlook (Unchanged) outlook

  • NoteIn the fiscal second quarter, we expect revenue and adjusted EBITDA to be sequentially higher than in the fiscal first quarter.
  • NoteThe Company intends to invest approximately $3.5 million over the next three years in growth capital improvements for Safari Flower Company.

What drove it

  • International medical cannabis net revenue increased to $43.3 million from $37.1 million, mainly due to higher sales in Germany driven by increased patient demand.
  • Canadian medical cannabis reimbursement rates were lowered by approximately 30% effective April 1, 2026.
  • The Company is winding down its consumer cannabis business and exiting its low-margin Canadian Consumer and Plant Propagation businesses.
  • Safari received EU-GMP certification for its Ontario facility on July 23, 2026, granted for a three-year term.
  • The increase in gross profit included an increase in gain on changes in fair value of biological assets of $12.6 million, partially offset by a decrease in net revenue of $6.5 million.

Concerns

  • Total net revenue declined 9% to 67,554 ($ thousands).
  • Adjusted gross margin before fair value adjustments on total net revenue declined to 58% from 64%.
  • Canadian medical cannabis net revenue declined 25% to 20,699 ($ thousands) following the reimbursement-program change.
  • Consumer cannabis net revenue declined to 2,060 ($ thousands) from 7,875 ($ thousands), and its adjusted gross margin before fair value adjustments declined to 20% from 33%.
  • Adjusted EBITDA declined to 3,443 ($ thousands) from 10,815 ($ thousands), while free cash flow moved to an outflow of (5,793) ($ thousands).

What to watch

  • Whether fiscal second-quarter revenue and adjusted EBITDA are sequentially higher than fiscal first-quarter levels, as management expects.
  • Growth in Germany and other international medical cannabis markets, which management identifies as its highest-margin markets.
  • The effect of reduced Canadian federal reimbursement rates on Canadian medical cannabis revenue and medical cannabis adjusted gross margin.
  • Safari's contribution to product availability, speed to market, manufacturing costs and international revenue growth following its EU-GMP certification.
  • Cash flow performance as the Company funds growth capital improvements and international sales initiatives.

Balance sheet and cash flow

  • $149.1 million of cash, cash equivalents and short-term investments with no debt.
  • Net cash provided by (used in) operating activities from continuing operations was (4,446) ($ thousands), compared to 7,679 ($ thousands) in the prior year period.
  • Free cash flow was (5,793) ($ thousands), compared to 6,772 ($ thousands) in the prior year period.
  • Working capital was 320,020 ($ thousands), compared to 308,416 ($ thousands) in the prior year period.
  • Safari acquisition closed on April 14, 2026. The Company intends to invest approximately $3.5 million over the next three years in growth capital improvements.

Analysis

Aurora reported a mixed fiscal 2027 first quarter. Total net revenue declined 9% to 67,554 ($ thousands) from 74,076 ($ thousands), as lower Canadian medical cannabis revenue and the consumer-cannabis wind-down outweighed growth in international medical cannabis and wholesale bulk cannabis. Medical cannabis revenue was broadly stable at 64,036 ($ thousands), with international medical cannabis up 17% to 43,337 ($ thousands), led by German patient demand, while Canadian medical cannabis declined 25% to 20,699 ($ thousands).

Margin performance weakened on the underlying measures. Adjusted gross margin before fair value adjustments on total net revenue declined to 58% from 64%, and the corresponding medical cannabis metric declined to 61% from 69%. Aurora attributed the medical margin pressure to Canadian federal reimbursement changes effective April 1, 2026, which lowered reimbursement rates by approximately 30%. Consumer cannabis adjusted gross margin before fair value adjustments declined to 20% from 33% as the Company sold products at reduced prices to reduce wind-down-related inventory impairments.

Reported profitability improved in selected IFRS measures, but adjusted earnings and cash generation deteriorated. Gross profit was 35,622 ($ thousands), compared with 33,528 ($ thousands), supported by an increase in gain on changes in fair value of biological assets of $12.6 million. Net loss from continuing operations narrowed to (4,033) ($ thousands) from (10,186) ($ thousands), helped by higher gross profit, lower operating expenses and higher other income. However, adjusted gross profit before fair value adjustments declined by $8.3 million, adjusted EBITDA fell to 3,443 ($ thousands) from 10,815 ($ thousands), and adjusted net income declined to 3,811 ($ thousands) from 6,598 ($ thousands).

Cash conversion was negative during the quarter. Net cash used in operating activities from continuing operations was (4,446) ($ thousands), and free cash flow was an outflow of (5,793) ($ thousands), compared with an inflow of 6,772 ($ thousands) in the prior-year period. Aurora reported $149.1 million of cash, cash equivalents and short-term investments with no debt, and working capital of 320,020 ($ thousands). The Company closed the Safari acquisition on April 14, 2026 and plans approximately $3.5 million of growth-capital investment over the next three years.

The full-year outlook was reiterated without quantitative targets. Management expects fiscal second-quarter revenue and adjusted EBITDA to be sequentially higher than the first quarter, supported by increasing global medical-cannabis patient demand, international sales initiatives and EU-GMP capacity expansion. Safari's July 23, 2026 EU-GMP certification, granted for three years, is central to the strategy to add supply capacity for high-margin international medical markets and reduce reliance on third-party suppliers.

Management, verbatim

We remain confident in our commercial execution, supported by our genetics program and regulatory and operational expertise which underpin our leadership in Canada, Germany, Poland, Australia, and New Zealand. These competitive advantages support our strategy to invest further in EU-GMP manufacturing capacity so that we can supply growing international markets for medical cannabis and thereby maintain and expand our market share.

Miguel Martin, Executive Chairman and Chief Executive Officer

The first quarter reflects our continued strength, as we delivered international revenue growth and leading adjusted gross margins 1, anchored by a cost structure designed to support topline growth. In the second quarter, we expect both revenue and Adjusted EBITDA 1 to improve sequentially, driven by increasing global patient demand for medical cannabis.

Miguel Martin, Executive Chairman and Chief Executive Officer

Not in the filing

stated, not guessed
  • GAAP or IFRS earnings per share and adjusted earnings per share were not reported.
  • Prior-quarter comparisons were not reported for the financial metrics.
  • Quantitative fiscal full-year 2027 revenue, gross margin, operating-expense and tax-rate guidance were not reported.
  • A prior outlook document was not provided, so comparison with prior guidance is unavailable.
  • Share repurchases, dividends and other capital-return activity were not reported.
  • Total debt amount, debt maturities and interest expense were not reported.
  • Cash, cash equivalents and short-term investments were reported as $149.1 million, but the filing did not provide a tabular period-end cash balance or prior-year cash comparison.
  • Revenue and profitability contribution from Safari Flower Company were not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about ACB earnings dates

When is Aurora Cannabis's next earnings date?
AlphAI has no date for ACB yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.